Needham analyst Scott Berg maintains Smartsheet (NYSE:SMAR) with a Buy and raises the price target from $80 to $100.
RedHill Biopharma Reaches Agreement In Principle With HCR To Extinguish All Debt Obligations In Exchange For Movantik
RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has reached a non-binding agreement in principle with HCR Collateral